In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to detect Harmless dosing regimen. Added contributors will probably be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In https://abbv-744andotherbrd4inhib24578.anchor-blog.com/12311877/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options